As AAV‐FGF21 gene therapy have resulted in marked reductions in bodyweight and insulin resistance in HFD feeding and ob/ob mice,62 FGF21 can be a potential target to treat obesity and insulin resistance. Here, FGF21 is linked to Insulin resistance.